Narrow search
Showing 1 - 10 of 890
Cover Image
Bedside Rapid Flu Test and Zanamivir Prescription in Healthy Working Adults: A Cost-Benefit Analysis
Schwarzinger, Michael; Housset, Bruno; Carrat, Fabrice - In: PharmacoEconomics 21 (2003) 3, pp. 215-224
Background: Zanamivir, a neuraminidase inhibitor, reduces the number of days of illness in influenza-positive patients …. New bedside rapid flu tests (RFT) should increase the number of influenza-positive patients whom receive zanamivir … appropriately. Objective: To estimate the economic effects of implementing RFT and zanamivir among unvaccinated healthy working …
Persistent link: https://www.econbiz.de/10005243184
Cover Image
Impact of Zanamivir Treatment on Productivity, Health Status and Healthcare Resource Use in Patients with Influenza
Aoki, Fred Y.; Fleming, Douglas M.; Griffin, Adrian D.; … - In: PharmacoEconomics 17 (2000) 2, pp. 187-195
Objective: This study examined the impact of zanamivir treatment on patient morbidity in patients with influenza … virologically confirmed influenza. Interventions: Two different zanamivir treatment regimens [twice daily (bid) or 4 times daily … zanamivir had additional contacts with healthcare professionals compared with those who received placebo (8 vs 14%; p <= 0 …
Persistent link: https://www.econbiz.de/10005243126
Cover Image
Cost-Effectiveness Analysis of Inhaled Zanamivir in the Treatment of Influenza A and B in High-Risk Patients
Griffin, Adrian D.; Perry, Andrew S.; Fleming, Douglas M. - In: PharmacoEconomics 19 (2001) 3, pp. 293-301
Objective: To evaluate the cost effectiveness of zanamivir 10mg twice daily for 5 days in the treatment of influenza in … clinical trials. Patients: A total of 154 zanamivir and 167 placebo high-risk patients were included in the analysis. Main …-effectiveness acceptability curves demonstrated 90% certainty that zanamivir would be cost effective at Lstg 8000 per QALY. Conclusions …
Persistent link: https://www.econbiz.de/10005404857
Cover Image
Influenza: Cost of Illness and Considerations in the Economic Evaluation of New and Emerging Therapies
Cram, Peter; Blitz, Susan G.; Monto, Arnold; Fendrick, … - In: PharmacoEconomics 19 (2001) 3, pp. 223-230
practice. The approval of the neuraminidase inhibitors (NIs) - zanamivir and oseltamivir - remind healthcare providers of the …
Persistent link: https://www.econbiz.de/10005590304
Cover Image
Economic Evaluations of Influenza Vaccination in the Elderly: Impact on Public Health Policy
Wood, Susan C.; Nguyen, Van Hung; Schmidt, Claudia - In: Disease Management and Health Outcomes 8 (2000) 5, pp. 273-285
Objective: To determine 1. whether influenza vaccination in the elderly is cost effective or cost saving compared with a non-intervention strategy and 2. whether it is worth framing a vaccination policy for this population. Background: Influenza causes substantial morbidity and mortality in...
Persistent link: https://www.econbiz.de/10005404702
Cover Image
Cost-Effectiveness Model of Cytomegalovirus Management Strategies in Renal Transplantation: Comparing Valaciclovir Prophylaxis with Current Practice
Mauskopf, Josephine A.; Richter, Anke; Annemans, Lieven; … - In: PharmacoEconomics 18 (2000) 3, pp. 239-251
Background: Cytomegalovirus (CMV) disease may occur following renal transplantation and has been shown to have health and cost consequences in this setting. Objective: To compare the cost effectiveness of different CMV management strategies for renal transplant patients: prophylaxis with (i)...
Persistent link: https://www.econbiz.de/10005449009
Cover Image
Cost Effectiveness of Human Immunodeficiency Virus Postexposure Prophylaxis for Healthcare Workers
Scheid, Dewey C.; Hamm, Robert M.; Stevens, Kevin W. - In: PharmacoEconomics 18 (2000) 4, pp. 355-368
Objective: The United States Public Health Service (USPHS) published recommendations for human immunodeficiency virus (HIV) postexposure prophylaxis (PEP) of healthcare workers in May 1998. The aim of this study was to analyse the cost effectiveness of the USPHS PEP guidelines. Design and...
Persistent link: https://www.econbiz.de/10005449098
Cover Image
The Cost Effectiveness of Antiretroviral Regimens for the Treatment of HIV/AIDS
Anis, Aslam H.; Guh, Daphne; Hogg, Robert S.; Wang, Xiao-Hua - In: PharmacoEconomics 18 (2000) 4, pp. 393-404
Objective: To estimate survival, the number of life-years gained and cost effectiveness of antiretroviral therapy (ART) regimens, denoted as ERA-I [zidovudine + (didanosine or zalcitabine)]; ERA-II [stavudine + (didanosine or zalcitabine) or lamivudine + (zidovudine or didanosine or zalcitabine...
Persistent link: https://www.econbiz.de/10005449111
Cover Image
Incremental Cost Effectiveness of Prophylaxis for Cytomegalovirus Disease in Patients with AIDS
Kempen, John H.; Frick, Kevin D.; Jabs, Douglas A. - In: PharmacoEconomics 19 (2001) 12, pp. 1199-1208
Cytomegalovirus (CMV) disease, an opportunistic complication in patients with AIDS, causes substantial morbidity and has high treatment costs. Although prevention of this disease is highly desirable, incremental cost-effectiveness estimates for proposed prophylactic strategies in the era prior...
Persistent link: https://www.econbiz.de/10005404898
Cover Image
Cost-Effectiveness Analysis of Lamivudine for the Treatment of Chronic Hepatitis B
Crowley, Steven J.; Tognarini, David; Desmond, Paul V.; … - In: PharmacoEconomics 17 (2000) 5, pp. 409-427
Objective: To estimate the short term and long term cost effectiveness, from a healthcare perspective, associated with the introduction of lamivudine for chronic hepatitis B. Design: The analysis used a 2-step modelling approach. A decision tree was used to estimate clinical outcomes and costs...
Persistent link: https://www.econbiz.de/10005405004